Di Sabatino Elena, Ferraro Diana, Gaetani Lorenzo, Emiliano Edoardo, Parnetti Lucilla, Di Filippo Massimiliano
Clinica Neurologica, Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Umbria, Italy.
Dipartimento di Neuroscienze, Ospedale Civile di Baggiovara, Azienda Ospedaliera-Università di Modena, Modena, Italy.
J Neurol. 2025 Feb 17;272(3):211. doi: 10.1007/s00415-025-12907-6.
The role of B cells in the pathophysiology of multiple sclerosis (MS) extends beyond antibody synthesis, also involving the modulation of T lymphocytes and myeloid cells. B-cell activation within the Central Nervous System is associated with the release of various antibodies, cytokines, and chemokines, measurable in biofluids, thereby serving as biomarkers of the immune processes responsible for MS. To this purpose, a biomarker-based characterization of the disease through the combination of well-established markers, e.g., immunoglobulin (Ig) G index, IgG oligoclonal bands, Ig free light chains, with new promising markers, namely chemokine (C-X-C motif) ligand 13, and B-cell activating factor/A proliferation-inducing ligand, might represent a significant improvement in the management of people with MS.
B细胞在多发性硬化症（MS）病理生理学中的作用不仅限于抗体合成，还涉及对T淋巴细胞和髓样细胞的调节。中枢神经系统内的B细胞活化与多种抗体、细胞因子和趋化因子的释放有关，这些物质可在生物流体中检测到，因此可作为MS相关免疫过程的生物标志物。为此，通过将成熟的标志物（如免疫球蛋白（Ig）G指数、IgG寡克隆带、游离轻链）与新的有前景的标志物（即趋化因子（C-X-C基序）配体13和B细胞活化因子/增殖诱导配体）相结合，基于生物标志物对该疾病进行特征描述，可能会显著改善MS患者的管理。
